ArdelyxARDX
About: Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Employees: 395
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
35% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 34
18% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 62
4% more funds holding
Funds holding: 201 [Q3] → 210 (+9) [Q4]
3.09% more ownership
Funds ownership: 60.59% [Q3] → 63.68% (+3.09%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]
22% less capital invested
Capital invested by funds: $982M [Q3] → $765M (-$218M) [Q4]
23% less call options, than puts
Call options by funds: $14.5M | Put options by funds: $18.9M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Scotiabank Louise Chen 27% 1-year accuracy 32 / 118 met price target | 173%upside $15 | Sector Outperform Initiated | 7 Mar 2025 |
Ladenburg Thalmann Aydin Huseynov 22% 1-year accuracy 2 / 9 met price target | 100%upside $11 | Buy Assumed | 7 Mar 2025 |
Raymond James Ryan Deschner 78% 1-year accuracy 7 / 9 met price target | 136%upside $13 | Strong Buy Reiterated | 21 Feb 2025 |
HC Wainwright & Co. Ed Arce 40% 1-year accuracy 61 / 151 met price target | 0%upside $5.50 | Neutral Reiterated | 21 Feb 2025 |
Financial journalist opinion
Based on 5 articles about ARDX published over the past 30 days









